Hematopoietic stem cell transplantation (HSCT) represents a curative option for those afflicted with numerous hematologic malignancies and bone marrow failure syndromes. Advances and refinement of the HSCT process have resulted in increasing number of transplants performed on older patients in the recent years. Pre-transplant assessments (PTA) function to risk stratify patients prior to undergoing HSCT in an effort to predict those at higher risk of treatment-related toxicity, to inform risk/benefit assessments and to aid clinical decision making. Traditionally used risk stratification parameters such as chronologic age, comorbidity and performance status may not fully capture physical function, physiologic fitness, highlighting a need for improvement in PTA. Incorporation of frailty measurements in pre-HSCT assessments, particularly in elderly transplant candidates, may result in improving predictive ability of existing tools such as the Hematopoietic Cell Transplantation Comorbidity Index and Karnofsky performance status. Here, we review existing pre-HSCT assessment tools, measures of frailty that may aid in risk stratification for patients undergoing HSCT and directions for future research using frailty in the pre-HSCT setting.
This is a preview of subscription content, access via your institution
Subscribe to Journal
Get full journal access for 1 year
only $9.92 per issue
All prices are NET prices.
VAT will be added later in the checkout.
Tax calculation will be finalised during checkout.
Get time limited or full article access on ReadCube.
All prices are NET prices.
D'Souza A, Zhu X Current Uses and Outcomes of Hematopoietic Cell Transplantation (HCT): CIBMTR Summary Slides, 2016. Available at: http://www.cibmtr.org.
McClune BL, Weisdorf DJ, Pedersen TL, Tunes d a Silva G, Tallman MS, Sierra J et al. Effect of age on outcome of reduced-intensity hematopoietic cell transplantation for older patients with acute myeloid leukemia in first complete remission or with myelodysplastic syndrome. J Clin Oncol 2010; 28: 1878–1887.
Storb R . Can reduced-intensity allogeneic transplantation cure older adults with AML? Best Pract Res Clin Haematol 2007; 20: 85–90.
Gooley TA, Chien JW, Pergam SA, Hingorani S, Sorror ML, Boeckh M et al. Reduced mortality after allogeneic hematopoietic-cell transplantation. N Engl J Med 2010; 363: 2091–2101.
Brunner AM, Kim HT, Coughlin E, Alyea EP, Armand P, Ballen KK et al. Outcomes in patients age 70 or older undergoing allogeneic hematopoietic stem cell transplantation for hematologic malignancies. Biol Blood Marrow Transplant 2013; 19: 1374–1380.
Rashidi A, Ebadi M, Colditz GA, DiPersio JF . Outcomes of allogeneic stem cell transplantation in elderly patients with acute myeloid leukemia: a systematic review and meta-analysis. Biol Blood Marrow Transplant 2016; 22: 651–657.
Shimoni A, Labopin M, Savani B, Volin L, Ehninger G, Kuball J et al. Long-term survival and late events after allogeneic stem cell transplantation from HLA-matched siblings for acute myeloid leukemia with myeloablative compared to reduced-intensity conditioning: a report on behalf of the acute leukemia working party of Eur. J Hematol Oncol 2016; 9: 118.
Koreth J, Aldridge J, Kim HT, Alyea EP, Cutler C, Armand P et al. Reduced-intensity conditioning hematopoietic stem cell transplantation in patients over 60 years: hematologic malignancy outcomes are not impaired in advanced age. Biol Blood Marrow Transplant 2010; 16: 792–800.
Pidala J, Craig BM, Lee SJ, Majhail N, Quinn G, Anasetti C . Practice variation in physician referral for allogeneic hematopoietic cell transplantation. Bone Marrow Transplant 2013; 48: 63–67.
Hamaker ME, Stauder R, van Munster BC . Exclusion of older patients from ongoing clinical trials for hematological malignancies: an evaluation of the National Institutes of Health Clinical Trial Registry. Oncologist 2014; 19: 1069–1075.
Townsley CA, Selby R, Siu LL . Systematic review of barriers to the recruitment of older patients with cancer onto clinical trials. J Clin Oncol 2005; 23: 3112–3124.
Sorror ML, Sandmaier BM, Storer BE, Franke GN, Laport GG, Chauncey TR et al. Long-term outcomes among older patients following nonmyeloablative conditioning and allogeneic hematopoietic cell transplantation for advanced hematologic malignancies. JAMA 2011; 306: 1874–1883.
Lazarevic V, Hörstedt A-S, Johansson B, Antunovic P, Billström R, Derolf A et al. Incidence and prognostic significance of karyotypic subgroups in older patients with acute myeloid leukemia: the Swedish population-based experience. Blood Cancer J 2014; 4: e188.
Appelbaum FR, Gundacker H, Head DR, Slovak ML, Willman CL, Godwin JE et al. Age and acute myeloid leukemia. Blood 2006; 107: 3481–3485.
Morley JE, Vellas B, van Kan GA, Anker SD, Bauer JM, Bernabei R et al. Frailty consensus: a call to action. J Am Med Dir Assoc 2013; 14: 392–397.
Ness KK, Krull KR, Jones KE, Mulrooney DA, Armstrong GT, Green DM et al. Physiologic frailty as a sign of accelerated aging among adult survivors of childhood cancer: a report from the St Jude Lifetime cohort study. J Clin Oncol 2013; 31: 4496–4503.
Arora M, Sun C, Ness K, Teh JB, Schad A, Hanby C et al. Older survivors of allogeneic hematopoietic cell transplantation (HCT) with chronic graft vs. host disease (cGvHD) demonstrate higher risk of frailty as compared with autologous HCT recipients: a report from the Bone Marrow Transplant Survivor Study-2. Biol Blood Marrow Transplant 2015; 21: S72–S73.
Collard RM, Boter H, Schoevers RA, Oude Voshaar RC . Prevalence of frailty in community-dwelling older persons: a systematic review. J Am Geriatr Soc 2012; 60: 1487–1492.
Artz A, Swanson K, Kocherginsky M, Godley L, Kline J, Nguyen V et al. Features of frailty are surprisingly common in adults 50 years and older undergoing allogeneic hematopoietic cell transplantation (HCT) in the modern era. Biol Blood Marrow Transplant 2011; 17: S302.
Muffly LS, Kocherginsky M, Stock W, Chu Q, Bishop MR, Godley LA et al. Geriatric assessment to predict survival in older allogeneic hematopoietic cell transplantation recipients. Haematologica 2014; 99: 1373–1379.
Arora M, Bhatia S, DeFor TE, Nayar M, Belete H, Lund T et al. Impact of frailty on hematopoietic cell on early transplant outcomes in older recipients. Blood 2015; 126: 388.
Arora M, Sun C-L, Ness KK, Teh JB, Wu J, Francisco L et al. Physiologic frailty in nonelderly hematopoietic cell transplantation patients. JAMA Oncol 2016; 2: 1277.
Wood WA, Krishnamurthy J, Mitin N, Torrice C, Parker JS, Snavely AC et al. Chemotherapy and stem cell transplantation increase p16INK4a expression, a biomarker of T-cell aging. EBioMedicine 2016; 11: 227–238.
Alfano CM, Peng J, Andridge RR, Lindgren ME, Povoski SP, Lipari AM et al. Inflammatory cytokines and comorbidity development in breast cancer survivors versus noncancer controls: evidence for accelerated aging? J Clin Oncol 2017; 35: 149–156.
Childs BG, Durik M, Baker DJ, van Deursen JM . Cellular senescence in aging and age-related disease: from mechanisms to therapy. Nat Med 2015; 21: 1424–1435.
Gupta V, Panzarella T, Li L, Khan J, Sharma A, Lipton JH et al. A prospective study comparing the outcomes and health-related quality of life in adult patients with myeloid malignancies undergoing allogeneic transplantation using myeloablative or reduced-intensity conditioning. Biol Blood Marrow Transplant 2012; 18: 113–124.
Pallua S, Giesinger J, Oberguggenberger A, Kemmler G, Nachbaur D, Clausen J et al. Impact of GvHD on quality of life in long-term survivors of haematopoietic transplantation. Bone Marrow Transplant 2010; 45: 1534–1539.
Pidala J, Kurland B, Chai X, Majhail N, Weisdorf DJ, Pavletic S et al. Patient-reported quality of life is associated with severity of chronic graft-versus-host disease as measured by NIH criteria: report on baseline data from the Chronic GVHD Consortium. Blood 2011; 117: 4651–4657.
Kurosawa S, Oshima K, Yamaguchi T, Yanagisawa A, Fukuda T, Kanamori H et al. Patient-reported quality of life after allogeneic hematopoietic cell transplantation according to types and severity of chronic Gvhd. Blood 2016; 128: 1240.
Sorror ML, Maris MB, Storb R, Baron F, Sandmaier BM, Maloney DG et al. Hematopoietic cell transplantation (HCT)-specific comorbidity index: a new tool for risk assessment before allogeneic HCT. Blood 2005; 106: 2912–2919.
Sorror ML, Logan BR, Zhu X, Rizzo JD, Cooke KR, McCarthy PL et al. Prospective validation of the predictive power of the Hematopoietic Cell Transplantation Comorbidity Index: a Center for International Blood and Marrow Transplant Research Study. Biol Blood Marrow Transplant 2015; 21: 1479–1487.
Sorror ML, Storer BE, Sandmaier BM, Maris M, Shizuru J, Maziarz R et al. Five-year follow-up of patients with advanced chronic lymphocytic leukemia treated with allogeneic hematopoietic cell transplantation after nonmyeloablative conditioning. J Clin Oncol 2008; 26: 4912–4920.
Sorror ML, Storb RF, Sandmaier BM, Maziarz RT, Pulsipher MA, Maris MB et al. Comorbidity-age index: a clinical measure of biologic age before allogeneic hematopoietic cell transplantation. J Clin Oncol 2014; 32: 3249–3256.
Sorror M, Storer B, Sandmaier BM, Maloney DG, Chauncey TR, Langston A et al. Hematopoietic cell transplantation-comorbidity index and Karnofsky performance status are independent predictors of morbidity and mortality after allogeneic nonmyeloablative hematopoietic cell transplantation. Cancer 2008; 112: 1992–2001.
Artz AS, Pollyea DA, Kocherginsky M, Stock W, Rich E, Odenike O et al. Performance status and comorbidity predict transplant-related mortality after allogeneic hematopoietic cell transplantation. Biol Blood Marrow Transplant 2006; 12: 954–964.
Sorensen JB, Klee M, Palshof T, Hansen HH . Performance status assessment in cancer patients. An inter-observer variability study. Br J Cancer 1993; 67: 773–775.
Chow R, Chiu N, Bruera E, Krishnan M, Chiu L, Lam H et al. Inter-rater reliability in performance status assessment among health care professionals: a systematic review. Ann Palliat Med 2016; 5: 83–92.
Kim YJ, Hui D, Zhang Y, Park JC, Chisholm G, Williams J et al. Differences in performance status assessment among palliative care specialists, nurses, and medical oncologists. J Pain Symptom Manage 2015; 49: 1050–1058.e2.
de Borja M-T, Chow E, Bovett G, Davis L, Gillies C . The correlation among patients and health care professionals in assessing functional status using the Karnofsky and Eastern Cooperative Oncology Group Performance Status Scales. Support Cancer Ther 2004; 2: 59–63.
Blagden SP, Charman SC, Sharples LD, Magee LRA, Gilligan D . Performance status score: do patients and their oncologists agree? Br J Cancer 2003; 89: 1022–1027.
Atkinson TM, Andreotti CF, Roberts KE, Saracino RM, Hernandez M, Basch E . The level of association between functional performance status measures and patient-reported outcomes in cancer patients: a systematic review. Support Care Cancer 2015; 23: 3645–3652.
Schnadig ID, Fromme EK, Loprinzi CL, Sloan JA, Mori M, Li H et al. Patient-physician disagreement regarding performance status is associated with worse survivorship in patients with advanced cancer. Cancer 2008; 113: 2205–2214.
Liu MA, Hshieh T, Condron N, Wadleigh M, Abel GA, Driver JA . Relationship between physician and patient assessment of performance status and survival in a large cohort of patients with haematologic malignancies. Br J Cancer 2016; 115: 858–861.
Armand P, Gibson CJ, Cutler C, Ho VT, Koreth J, Alyea EP et al. A disease risk index for patients undergoing allogeneic stem cell transplantation. Blood 2012; 120: 905–913.
Armand P, Kim HT, Logan BR, Wang Z, Alyea EP, Kalaycio ME et al. Validation and refinement of the Disease Risk Index for allogeneic stem cell transplantation. Blood 2014; 123: 3664–3671.
Jones DM, Song X, Rockwood K . Operationalizing a frailty index from a standardized comprehensive geriatric assessment. J Am Geriatr Soc 2004; 52: 1929–1933.
Mitnitski A, Song X, Skoog I, Broe G, Cox JL, Grunfeld E et al. Relative fitness and frailty of elderly men and women in developed countries and their relationship with mortality. J Am Geriatr Soc 2005; 53: 2184–2189.
Rockwood K, Mitnitski A, Song X, Steen B, Skoog I . Long-term risks of death and institutionalization of elderly people in relation to deficit accumulation at age 70. J Am Geriatr Soc 2006; 54: 975–979.
Extermann M, Hurria A . Comprehensive geriatric assessment for older patients with cancer. J Clin Oncol 2007; 25: 1824–1831.
Tucci A, Ferrari S, Bottelli C, Borlenghi E, Drera M, Rossi G . A comprehensive geriatric assessment is more effective than clinical judgment to identify elderly diffuse large cell lymphoma patients who benefit from aggressive therapy. Cancer 2009; 115: 4547–4553.
Fried LP, Tangen CM, Walston J, Newman AB, Hirsch C, Gottdiener J et al. Frailty in older adults: evidence for a phenotype. J Gerontol A Biol Sci Med Sci 2001; 56: M146–M156.
Fried LP, Ferrucci L, Darer J, Williamson JD, Anderson G . Untangling the concepts of disability, frailty, and comorbidity: implications for improved targeting and care. J Gerontol A Biol Sci Med Sci 2004; 59: 255–263.
Rothman MD, Leo-Summers L, Gill TM . Prognostic significance of potential frailty criteria. J Am Geriatr Soc 2008; 56: 2211–2216.
Mitnitski AB, Mogilner AJ, Rockwood K . Accumulation of deficits as a proxy measure of aging. Sci World J 2001; 1: 323–336.
Mitnitski AB, Graham JE, Mogilner AJ, Rockwood K . Frailty, fitness and late-life mortality in relation to chronological and biological age. BMC Geriatr 2002; 2: 1.
Freyer G, Geay J-F, Touzet S, Provencal J, Weber B, Jacquin J-P et al. Comprehensive geriatric assessment predicts tolerance to chemotherapy and survival in elderly patients with advanced ovarian carcinoma: a GINECO study. Ann Oncol Off J Eur Soc Med Oncol 2005; 16: 1795–1800.
Extermann M, Aapro M, Bernabei R, Cohen HJ, Droz J-P, Lichtman S et al. Use of comprehensive geriatric assessment in older cancer patients: recommendations from the task force on CGA of the International Society of Geriatric Oncology (SIOG). Crit Rev Oncol Hematol 2005; 55: 241–252.
Muffly LS, Boulukos M, Swanson K, Kocherginsky M, Cerro P, del, Schroeder L et al. Pilot study of comprehensive geriatric assessment (CGA) in allogeneic transplant: CGA captures a high prevalence of vulnerabilities in older transplant recipients. Biol Blood Marrow Transplant 2013; 19: 429–434.
Clegg A, Bates C, Young J, Ryan R, Nichols L, Ann Teale E et al. Development and validation of an electronic frailty index using routine primary care electronic health record data. Age Ageing 2016; 45: 353–360.
Hamaker ME, Jonker JM, de Rooij SE, Vos AG, Smorenburg CH, van Munster BC . Frailty screening methods for predicting outcome of a comprehensive geriatric assessment in elderly patients with cancer: a systematic review. Lancet Oncol 2012; 13: e437–e444.
Pijpers E, Ferreira I, Stehouwer CDA, Nieuwenhuijzen Kruseman AC . The frailty dilemma. Review of the predictive accuracy of major frailty scores. Eur J Intern Med 2012; 23: 118–123.
Artz AS, Logan BR, Zhu X, Akpek G, Martino R, Gupta V et al. Pre-transplant C-reactive protein (CRP), ferritin and albumin as biomarkers to predict transplant related mortality (trm) after allogeneic hematopoietic cell transplant (HCT). Blood 2014; 124: 422.
Roubenoff R, Parise H, Payette HA, Abad LW, D’Agostino R, Jacques PF et al. Cytokines, insulin-like growth factor 1, sarcopenia, and mortality in very old community-dwelling men and women: the Framingham Heart Study. Am J Med 2003; 115: 429–435.
Harris TB, Ferrucci L, Tracy RP, Corti MC, Wacholder S, Ettinger WH et al. Associations of elevated interleukin-6 and C-reactive protein levels with mortality in the elderly. Am J Med 1999; 106: 506–512.
Proctor MJ, Morrison DS, Talwar D, Balmer SM, Fletcher CD, O’Reilly DSJ et al. A comparison of inflammation-based prognostic scores in patients with cancer. A Glasgow Inflammation Outcome Study. Eur J Cancer 2011; 47: 2633–2641.
Rosko A, Hofmeister C, Benson D, Efebera Y, Huang Y, Gillahan J et al. Autologous hematopoietic stem cell transplant induces the molecular aging of T-cells in multiple myeloma. Bone Marrow Transplant 2015; 50: 1379–1381.
Gadalla SM, Wang T, Loftus D, Friedman L, Dagnall C, Haagenson MD et al. Donor telomere length and outcomes after allogeneic unrelated hematopoietic cell transplant in patients with acute leukemia. Blood 2016; 128: 520.
Gadalla SM, Wang T, Dagnall C, Haagenson M, Spellman SR, Hicks B et al. Effect of recipient age and stem cell source on the association between donor telomere length and survival after allogeneic unrelated hematopoietic cell transplantation for severe aplastic anemia. Biol Blood Marrow Transplant 2016; 22: 2276–2282.
Jacobsen PB, Le-Rademacher J, Jim H, Syrjala K, Wingard JR, Logan B et al. Exercise and stress management training prior to hematopoietic cell transplantation: Blood and Marrow Transplant Clinical Trials Network (BMT CTN) 0902. Biol Blood Marrow Transplant 2014; 20: 1530–1536.
Beswick AD, Rees K, Dieppe P, Ayis S, Gooberman-Hill R, Horwood J et al. Complex interventions to improve physical function and maintain independent living in elderly people: a systematic review and meta-analysis. Lancet (London, England) 2008; 371: 725–735.
Cadore EL, Rodríguez-Mañas L, Sinclair A, Izquierdo M . Effects of different exercise interventions on risk of falls, gait ability, and balance in physically frail older adults: a systematic review. Rejuvenation Res 2013; 16: 105–114.
Theou O, Stathokostas L, Roland KP, Jakobi JM, Patterson C, Vandervoort AA et al. The effectiveness of exercise interventions for the management of frailty: a systematic review. J Aging Res 2011; 2011: 569194.
Wiskemann J, Dreger P, Schwerdtfeger R, Bondong A, Huber G, Kleindienst N et al. Effects of a partly self-administered exercise program before, during, and after allogeneic stem cell transplantation. Blood 2011; 117: 2604–2613.
Oswald WD, Gunzelmann T, Rupprecht R, Hagen B . Differential effects of single versus combined cognitive and physical training with older adults: the SimA study in a 5-year perspective. Eur J Ageing 2006; 3: 179–192.
Srinivas-Shankar U, Roberts SA, Connolly MJ, O’Connell MDL, Adams JE, Oldham JA et al. Effects of testosterone on muscle strength, physical function, body composition, and quality of life in intermediate-frail and frail elderly men: a randomized, double-blind, placebo-controlled study. J Clin Endocrinol Metab 2010; 95: 639–650.
Borst SE, Millard WJ, Lowenthal DT . Growth hormone, exercise, and aging: the future of therapy for the frail elderly. J Am Geriatr Soc 1994; 42: 528–535.
Muir SW, Montero-Odasso M . Effect of Vitamin D supplementation on muscle strength, gait and balance in older adults: a systematic review and meta-analysis. J Am Geriatr Soc 2011; 59: 2291–2300.
Fiatarone MA, O’Neill EF, Ryan ND, Clements KM, Solares GR, Nelson ME et al. Exercise training and nutritional supplementation for physical frailty in very elderly people. N Engl J Med 1994; 330: 1769–1775.
Loprinzi CL, Ellison NM, Schaid DJ, Krook JE, Athmann LM, Dose AM et al. Controlled trial of megestrol acetate for the treatment of cancer anorexia and cachexia. J Natl Cancer Inst 1990; 82: 1127–1132.
Yeh S-S, Wu S-Y, Lee T-P, Olson JS, Stevens MR, Dixon T et al. Improvement in quality-of-life measures and stimulation of weight gain after treatment with megestrol acetate oral suspension in geriatric cachexia: results of a double-blind, placebo-controlled study. J Am Geriatr Soc 2000; 48: 485–492.
Sullivan DH, Roberson PK, Smith ES, Price JA, Bopp MM . Effects of muscle strength training and megestrol acetate on strength, muscle mass, and function in frail older people. J Am Geriatr Soc 2007; 55: 20–28.
Jatoi A, Windschitl HE, Loprinzi CL, Sloan JA, Dakhil SR, Mailliard JA et al. Dronabinol versus megestrol acetate versus combination therapy for cancer-associated anorexia: a North Central Cancer Treatment Group study. J Clin Oncol 2002; 20: 567–573.
Kardinal CG, Loprinzi CL, Schaid DJ, Hass AC, Dose AM, Athmann LM et al. A controlled trial of cyproheptadine in cancer patients with anorexia and/or cachexia. Cancer 1990; 65: 2657–2662.
Volicer L, Stelly M, Morris J, McLaughlin J, Volicer BJ . Effects of dronabinol on anorexia and disturbed behavior in patients with Alzheimer’s disease. Int J Geriatr Psychiatry 1997; 12: 913–919.
Khatcheressian J, Cassel JB, Lyckholm L, Coyne P, Hagenmueller A, Smith TJ . Improving palliative and supportive care in cancer patients. Oncology (Williston Park) 2005; 19: 1365–1376; discussion 1377–8, 1381–2, 1384 passim.
Elsayem A, Swint K, Fisch MJ, Palmer JL, Reddy S, Walker P et al. Palliative care inpatient service in a comprehensive cancer center: clinical and financial outcomes. J Clin Oncol 2004; 22: 2008–2014.
Zimmermann C, Swami N, Krzyzanowska M, Hannon B, Leighl N, Oza A et al. Early palliative care for patients with advanced cancer: a cluster-randomised controlled trial. Lancet 2014; 383: 1721–1730.
Bakitas MA, Tosteson TD, Li Z, Lyons KD, Hull JG, Li Z et al. Early versus delayed initiation of concurrent palliative oncology care: patient outcomes in the ENABLE III randomized controlled trial. J Clin Oncol 2015; 33: 1438–1445.
Temel JS, Greer JA, Muzikansky A, Gallagher ER, Admane S, Jackson VA et al. Early palliative care for patients with metastatic non-small-cell lung cancer. N Engl J Med 2010; 363: 733–742.
El-Jawahri A, LeBlanc T, VanDusen H, Traeger L, Greer JA, Pirl WF et al. Effect of inpatient palliative care on quality of life 2 weeks after hematopoietic stem cell transplantation. JAMA 2016; 316: 2094.
Loggers ET, LeBlanc TW, El-Jawahri A, Fihn J, Bumpus M, David J et al. Pretransplantation supportive and palliative care consultation for high-risk hematopoietic cell transplantation patients. Biol Blood Marrow Transplant 2016; 22: 1299–1305.
Studenski S, Perera S, Patel K, Rosano C, Faulkner K, Inzitari M et al. Gait speed and survival in older adults. JAMA 2011; 305: 50.
Guralnik JM, Ferrucci L, Pieper CF, Leveille SG, Markides KS, Ostir GV et al. Lower extremity function and subsequent disability: consistency across studies, predictive models, and value of gait speed alone compared with the short physical performance battery. J Gerontol A Biol Sci Med Sci 2000; 55: M221–M231.
Hardy SE, Perera S, Roumani YF, Chandler JM, Studenski SA . Improvement in usual gait speed predicts better survival in older adults. J Am Geriatr Soc 2007; 55: 1727–1734.
Wennie Huang W-N, Perera S, VanSwearingen J, Studenski S . Performance measures predict onset of activity of daily living difficulty in community-dwelling older adults. J Am Geriatr Soc 2010; 58: 844–852.
Viccaro LJ, Perera S, Studenski SA . Is timed up and go better than gait speed in predicting health, function, and falls in older adults? J Am Geriatr Soc 2011; 59: 887–892.
Jones LW, Devlin SM, Maloy MA, Wood WA, Tuohy S, Espiritu N et al. Prognostic importance of pretransplant functional capacity after allogeneic hematopoietic cell transplantation. Oncologist 2015; 20: 1290–1297.
Syddall HE, Westbury LD, Dodds R, Dennison E, Cooper C, Sayer AA . Mortality in the Hertfordshire Ageing Study: association with level and loss of hand grip strength in later life. Age Ageing 2017; 46: 407–412.
Gawel J, Vengrow D, Collins J, Brown S, Buchanan A, Cook C . The short physical performance battery as a predictor for long term disability or institutionalization in the community dwelling population aged 65 years old or older. Phys Ther Rev 2012; 17: 37–44.
Cesari M, Cerullo F, Zamboni V, Di Palma R, Scambia G, Balducci L et al. Functional status and mortality in older women with gynecological cancer. J Gerontol A Biol Sci Med Sci 2013; 68: 1129–1133.
Brown JC, Harhay MO, Harhay MN . Physical function as a prognostic biomarker among cancer survivors. Br J Cancer 2015; 112: 194–198.
Palumbo A, Bringhen S, Mateos M-V, Larocca A, Facon T, Kumar SK et al. Geriatric assessment predicts survival and toxicities in elderly myeloma patients: an International Myeloma Working Group report. Blood 2015; 125: 2068–2074.
Baitar A, Van Fraeyenhove F, Vandebroek A, De Droogh E, Galdermans D, Mebis J et al. Evaluation of the Groningen Frailty Indicator and the G8 questionnaire as screening tools for frailty in older patients with cancer. J Geriatr Oncol 2013; 4: 32–38.
Smets IH, Kempen GI, Janssen-Heijnen ML, Deckx L, Buntinx FJ, van den Akker M et al. Four screening instruments for frailty in older patients with and without cancer: a diagnostic study. BMC Geriatr 2014; 14: 26.
Biganzoli L, Boni L, Becheri D, Zafarana E, Biagioni C, Cappadona S et al. Evaluation of the cardiovascular health study (CHS) instrument and the Vulnerable Elders Survey-13 (VES-13) in elderly cancer patients. Are we still missing the right screening tool? Ann Oncol Off J Eur Soc Med Oncol 2013; 24: 494–500.
Kenis C, Decoster L, Van Puyvelde K, De Grève J, Conings G, Milisen K et al. Performance of two geriatric screening tools in older patients with cancer. J Clin Oncol 2014; 32: 19–26.
The authors declare no conflict of interest.
About this article
Cite this article
Hegde, A., Murthy, H. Frailty: the missing piece of the pre- hematopoietic cell transplantation assessment?. Bone Marrow Transplant 53, 3–10 (2018). https://doi.org/10.1038/bmt.2017.192
This article is cited by
Bone Marrow Transplantation (2022)
Bone Marrow Transplantation (2022)
Current Oncology Reports (2022)
Is comprehensive geriatric testing guiding in the identification of multiple myeloma patients who are candidates for autologous stem cell transplantation? A prospective analysis
Annals of Hematology (2022)
Pilot prospective study of Frailty and Functionality in routine clinical assessment in allogeneic hematopoietic cell transplantation
Bone Marrow Transplantation (2021)